Takeda announced a strategic collaboration with NuBiyota LLC for the development of Microbial Ecosystem Therapeutic products for gastroenterology (GI) indications with a high unmet medical need.
Takeda and NuBiyota will collaborate to advance oral microbial consortia products developed by using NuBiyota’s microbiome platform for GI indications. NuBiyota will receive an upfront payment and is eligible for success-based development, regulatory and commercial milestones and tiered royalties based on net sales. Further details of the agreement were not disclosed.
“We are excited to partner with NuBiyota as this collaboration reinforces Takeda’s long-term commitment to unmet medical need in gastroenterology and adds to our other microbiome-related partnerships,” said Asit Parikh, M.D., Ph.D., head of Takeda’s gastroenterology therapeutic area unit. “Through these partnerships, we are exploring both microbial consortia and microbiome derived bioactives to investigate how the microbiome can be harnessed for treatment of GI diseases.”
NuBiyota’s Microbial Ecosystem Therapeutic is a clinic-ready microbial consortia which provides an entry point for clinical evaluation of microbiome based therapeutics which will enhance understanding of the role of microbiota in GI disease.
Filed Under: Drug Discovery